**Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas**

Ilya Ulasov¹, Bart Thaci¹, Purvaba Sarvaiya¹, Ruiyang Yi¹, Donna Guo¹, Brenda Auffinger¹, Peter Pytel², Lingjiao Zhang¹, Chung Kwon Kim¹, Anton Borovjagin³, Mahua Dey¹, Yu Han¹, Anatoly Y. Baryshnikov⁴ & Maciej S. Lesniak¹

¹The Brain Tumor Center, The University of Chicago, Chicago, Illinois 60637
²Department of Pathology, The University of Chicago, Chicago, Illinois 60637
³Department of Periodontology, School of Dentistry UAB, Birmingham, Alabama 35294
⁴Institute of Experimental Biotherapy, NN Blokhin Research Cancer Center, RAMS Kashirskoe Shosse 24, Moscow, Russia

**Abstract**

Metalloproteinases are membrane-bound proteins that play a role in the cellular responses to anti-glioma therapy. Previously, it has been shown that treatment of glioma cells with temozolomide (TMZ) and radiation (XRT) induces the expression of metalloproteinase 14 (MMP14). To investigate the role of MMP14 in gliomagenesis, we used several chemical inhibitors which affect MMP14 expression. Of all the inhibitors tested, we found that Marimastat not only inhibits the expression of MMP14 in U87 and U251 glioma cells, but also induces cell cycle arrest. To determine the relationship between MMP14 inhibition and alteration of the cell cycle, we used an RNAi technique. Genetic knockdown of MMP14 in U87 and U251 glioma cells induced G2/M arrest and decreased proliferation. Mechanistically, we show that TMZ and XRT regulated expression of MMP14 in clinical samples and in vitro models through downregulation of microRNA374. In vivo genetic knockdown of MMP14 significantly decreased tumor growth of glioma xenografts and improved survival of glioma-bearing mice. Moreover, the combination of MMP14 silencing with TMZ and XRT significantly improved the survival of glioma-bearing mice compared to a single modality treatment group. Therefore, we show that the inhibition of MMP14 sensitizes tumor cells to TMZ and XRT and could be used as a future strategy for antiglioma therapy.

**Introduction**

Glioblastoma multiforme (GBM), the most common primary brain tumor, is a devastating disease associated with high mortality [1]. Although most of the patients partially respond to adjuvant chemotherapy such as TMZ and XRT, tumor recurrence is inevitable [2, 3]. Similar to other cancers, glioma initiation and its relapse result from aberrant activation of the genes responsible for tumor invasion, proliferation, and cell division, including MMPs [4, 5]. Membrane-bound MMPs such as MMP14 are induced in response to TMZ and XRT and are also associated with extracellular matrix degradation [6, 7]. Thus, understanding the regulation of MMP14 will help in the development of new approaches for anticancer therapy.

MMP14 (MT1-MMP) is a membrane-type metalloproteinase with collagenase activity and has been implicated to play a role in many biological processes in normal and tumor tissues [8]. Although majority of the studies involving MMP14 primarily focus on angiogenesis [9, 10] and invasion [11, 12], recent studies have also pointed to the involvement of MMP14 in tumor proliferation [13] and remodeling of extracellular matrix and basement membrane [14].

In the present study, we explored the role of MMP14 in the pathogenesis of glioma. We show that MMP14 correlates with glioma aggressiveness and patient survival. Moreover, the MMP14 inhibitor, Marimastat, induces glioma cell cycle arrest and slows tumor progression. Genetic silencing of MMP14 positively correlates with...
G2/M arrest and sensitizes glioma cells to TMZ and XRT in vitro and in vivo in an orthotopic glioma model.

Material and Methods

Patient specimen and ethical statement

To analyze the expression of MMP14 in glioma patient’s tissues, we obtained a tissue microarray (TMA) provided by US Biomax (Rockville, MD) and supplemented these data by the staining of brain tumor specimens obtained from patients undergoing brain tumor resection at the University of Chicago Medical Center. These samples were collected from ongoing craniotomy, decoded and graded by neuropathologist. Each tissue specimen contained at least 90% cancer cells. The study was approved the Institutional Review Board (IRB) at the University of Chicago.

Cell lines

The human gliomas U87, T98, and U118 were purchased from ATCC (Manassas, VA). GBM patient-based GBM39 and GBM43 were provided by Dr. D. James (University of California at San Francisco). The U251 cells were kindly provided by Dr. Atique Ahmed (The University of Chicago). N10 were obtained from Japan Tissue Bank (Tokyo, Japan). All cell lines were cultured in monolayer in T75 cm² flasks in either MEM (for U87 and U118) or DMEM (U251, N10, T98) supplemented with 10% FBS (U87, U118, U251, N10, T98, and GBM39) or 1% (GBM43), 100 U/mL penicillin, 100 µg/mL streptomycin, at 37°C in a humidified atmosphere with 5% CO₂.

Drugs and treatments

CP101537, CP471474, and Marimastat were purchased from Sigma chemicals (St. Louis, MO) and dissolved either in dimethyl sulfoxide (DMSO) (CP101537 and CP471474) or in milliQ water (Marimastat) to obtain a stock concentration of 3.8 mMmol/L. The aliquots of the stock were stored in minus 20°C. TMZ was provided by Schering Plough-Merck (Whitehouse Station, NJ) and dissolved in DMSO to obtain a 100 mmol/L stock as suggested by the vendor. The radiation exposure was conducted by using the Gamma Cell 1000 (Nordion, Canada) unit. In vitro, cells were treated with 4 Gy daily for three consecutive days.

Flow cytometry

Cell cycle analysis was done as previously described [15]. Briefly, at selected time points, treated/untreated cells were fixed using 70% ethanol and then stored at minus 20°C for 24 h. The PI-stained nuclei cells (50 µg/mL of propidium iodide and 0.5 mg/mL of RNase A for 30 min at 37°C) were analyzed using a FACsaria (San Jose, CA). The distribution of the cells was evaluated by using the cell cycle template with (FJo).

Cell proliferation and cell viability assays

To determine the effect of drugs on glioma cell proliferation, plated cells were treated with DMSO, Marimastat, TMZ (100 µmol/L), XRT (4 Gy/daily, three consequent exposures), or a combination of them. At selected time points, cell proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Cell proliferation kit I, Roche, Indianapolis, IN) by adding 20 µL of MTT substrate to each well. After 3 h of incubation at 37°C and 5% CO₂, 100 µL of sodium dodecyl sulphate (SDS)-based stop solution was added to each well to stop the enzymatic reaction. On the following day, the absorbance was measured by the Multiscan MS microplate reader with a reference at 650 serving as a blank.

Lentivirus design and infection

Target cells were plated 24 h before infection and next day transduced with either shRNA plasmids (shScramble: GCACCTACCCAGCTTCTCAACTGATATCTACT; MMP14sh2: CTACCAACAGGGCTTCTGAGCC; MMP14sh4: ATGGAAAATCAGTCGCTCCGCTTCTGGTCTTG; MMP14sh5: ACTCTGCGCAGGCTTCTGGAGTCTCAGGAAT (Origene USA, Rockville, MA) or infected with shRNA lentivirus transduction particles containing either control shRNA (SHC002V, CAACAAGATGAAGAGACCACTCGAGTGTGTCCTCCTGATCTCTTGTGTGTTT) or shRNA specific for human MMP14 gene (NM_004995.2, CCGGCGGCCTTCTGTTTCTCCGATTTACTCGAGTTTATCTAGGA ACAAGGAGGCGCGTTTGG, Sigma Chemicals) for 48 h at 37°C and 5% CO₂ in the presence of 8 µg/mL of hexamethidine bromide (Sigma). Efficacy of the knockdown was checked by Western.

miRNA isolation and quantitative PCR

Total miRNA was isolated by using miRNeasy isolation kit (Qiagen, Dusseldorf, Germany) and then transcribed by using qScript microRNA cDNA synthesis kit (Quanta Biosciences, Gaithersburg, MD). To determine the expression of miRNAs induced by TMZ and XRT, we utilized a miFinder SAbscience array. The fold expression of each microRNAs was evaluated based on normalization [16]. The expression of selected miRNAs was validated via real time polymerase chain reaction (PCR) using Opticon 2 Instrument (Bio-Rad, Hercules, CA), SYBRgreen Super-
Mix (Quanta Biosciences), gene-specific primers synthesized by (www.RealTimePrimers.com) and microRNA PCR assays (Quanta Biosciences). Relative expression of target genes was normalized to the expression of RNU6 house keeping miRNA. Each sample was analyzed in triplicates. The analysis of experimental data was done using ΔΔCt method.

**Western blotting**

To detect expression of MMP14, cytosolic fraction (supernatant prepared using MEM-PER membrane protein extraction kit, Thermo Scientific, Hanover Park, IL) was mixed with 4× Laemmle buffer (Boston Bio product, MA) and subjected to 4–20% SDS-PAGE (sodiumdodecyl sulphate polyacrylamide gel electrophoresis) precast gel (Bio-Rad, Hercules, CA). Forty micrograms of the extracted proteins were transferred to the polyvinilidene fromride (PVDF) membrane and were probed with anti-MMP14 antibody (Abgent, San Diego, CA). In addition, blots were probed with antiactin antibody (AC-15, Sigma) for detection of β-actin as a loading control. Membrane-bound primary antibodies were detected by either horseradish peroxidase-conjugated secondary anti-mouse (sc-2031, Santa Cruz Biotechnology, Santa Cruz, CA) or anti-rabbit (sc-2030, Santa Cruz Biotechnology) antibodies. The protein bands were detected using Western C enhanced solution (Bio-Rad, Hercules, CA) and images were acquired by using gel doc documentations system (Bio-Rad).

**In vivo model**

Six-week-old female athymic nude mice (Charles River, Wilmington, MA) were used in these studies. To evaluate the impact of MMP14 knockdown on glioma growth in vivo, we established brain tumor xenografts by using 2.5 × 10⁴ cells (U87shScramble, U87shMMP14, U251sh Scramble, and U251shMMP14) per mouse. To determine the survival of glioma bearing mice in the presence of TMZ and XRT, 2.5 × 10⁴ U251shScramble or U251shMMP14 cells were implanted intracranially. Seven days later, each group of the mice was randomly divided into two groups to receive treatment with either DMSO or combination of TMZ (5 mg/kg, i.p.) followed by XRT, 2 Gy/kg with a 3 h lag time between treatments as suggested by Galban et al. [17]. All treatments were administered once a week for a 5-week period. Based on our preliminary dose-escalating experiments, we identified that TMZ (5 mg/kg) and 2 Gy/kg as minimally efficacious doses at multiple doses instead of one weekly dose and the schedule combination was chosen for our GBM mouse model to yield enhanced survival.

![Figure 1](image-url)

Figure 1. Upregulation of MMP14 prolongs survival of glioma patients. (A) Relationship between MMP14 expression and glioma progression was evaluated using hematoxylin and eosin (H&E) and MMP14 staining of glioblastoma multiforme (GBM) specimens obtained at the University of Chicago. Magnification 400×; (B) Distribution of MMP14 expression in different grades of brain tumors (N = 98 in total); (C) MMP14 affects mean survival time of GBM patients. Eighteen clinical samples were stained with MMP14, scored using three tier system and classified into low MMP14 (IHC score “0” and “1+”) or high MMP14 group (score “2+” and “3+”); Fisher’s exact test (*P < 0.05, **P < 0.01, ***P < 0.001).
survival in combination with MMP14 attenuation. The survival rate of the mice was determined at the end of the experiments and the results were plotted as Kaplan–Meier survival for each of the group.

Immunohistochemistry

Immunostaining was conducted on formalin-fixed paraffin embedded tissue specimens. After standard antigen retrieval, slides were incubated with either Ki-67 (Thermo Scientific) or anti-MMP14 antibodies (Abgent) following by incubation with VECTASTAIN Elite ABC Kit (Vector laboratories, Burlingame, CA). To acquire IHC images and calculate tumor volume, slides were scanned using 3D Histech Panoramic Scanner (Perkin Elmer, Downers Grove, IL) followed by analyses with Panoramic view software as proposed by Grommes et al. [18]. To evaluate the expression of MMP14 in the clinical settings we used a three tier score. We defined our scoring based on percentage of the cells expressing MMP14: “0,” <5% cells; “1+,” 5–20%; “2+,” 20–40%; “3+,” >40%.

Statistical analysis

All experiments have been performed at least twice in triplicates under identical conditions. Data are expressed as mean ± SEM. All statistical tests were performed using GraphPad Prism 4 or STATA 12 (GraphPad Software, Inc., La Jolla, CA). A P-value less than 0.05 was considered statistically significant.

Results

MMP14 expression is significantly increased in TMZ/XRT-treated glioma tissues

Accumulating evidence suggests that exposure of the tumor cells to chemotherapeutic drugs causes upregula-
tion of stress response genes such as proinflammatory cytokines and MMPs [19, 20]. As the treatment of brain tumor cells with chemotherapy has been shown to induce the expression of MMPs [21], we wanted to determine if there was a link between the expression of MMPs and the mortality of the patients with brain tumors. To establish the correlation between MMP14 expression and glioma grade, we stained a TMA containing 98 glioma samples with MMP14 antibodies in duplicates. The representative images and distribution of the MMP14-positive cases among clinical samples were plotted (Fig. 1A and B). Specifically, the percentage of MMP14-positive cases having “1+” and “2+” scores increased from 43% in grade 2 (n = 23, P < 0.001 vs. grade 4) to 60% in grade 3, (n = 25, P < 0.05) and 80% in grade 4 (n = 33, P < 0.05).

Despite a clear correlation between MMP14 expression and tumor grade, it remains unclear whether expression of MMP14 has any prognostic significance. To determine that, we stained a set of surgically resected GBM specimens obtained at the University of Chicago. We separated the GBM samples based on low (“0” and “1+”) and high (“2+”) expression of MMP14 and calculated the average of monthly survival based on medical records. As shown in Figure 1C, patients with high MMP14 immunoreactivities had shorter mean survival time compared to those with low MMP14 immunoreactivities (18.25 ± 3.98, n = 10 vs. 53.22 ± 9.39, n = 7, P = 0.0014). Data presented in Figure 1B and C accounts for all GBM specimens, however, does not take into consideration the impact of TMZ/XRT therapy on glioma progression and expression of MMP14. Therefore, we divided 18 GBM specimens into TMZ/XRT treated and untreated group and evaluated distribution of MMP14 stainings. As seen in Figure S1, patients with treated glioblastoma exhibit strong level of MMP14 immunoreactivity compared to the untreated cases.

Marimastat inhibits the proliferation of glioma cells

As the studies mentioned above suggest that MMP14 is upregulated during the course of therapy, we wanted to demonstrate whether MMP14 targeting can be a feasible antiglioma approach. To evaluate that, we treated glioma cells with a panel of MMP14 inhibitors CP101537, CP471474, and Marimastat, (Sigma-Aldrich Corp) that have previously been tested in treatment of glioma [22–24]. We selected U87, U251, and patient-derived GBM39 and GBM43 cells because of the difference they exhibit in the expression level of MMP14 (Fig. 2A) and sensitivities to the treatment with TMZ and XRT [25, 26]. Among the drugs (Marimastat, CP101537, and CP471474) that were preliminarily tested on U87 and in U251 cells, only Marimastat demonstrated inhibition of MMP14 expression (data not shown). As seen in Figure 2B, the treatment of gliomas with 100 nmol/L of Marimastat significantly inhibits the expression of MMP14 in U251, U87, GBM39, and GBM43 tumor cells. To evaluate whether the inhibition of MMP14 affects cell proliferation, we performed an MTT assay (Fig. 2C). In this experiment, we observed that GBM39, GBM43, and U87 cells have higher sensitivity to Marimastat compared to the

Figure 3. Genetic silencing of MMP14 results in glioma G2/M arrest. (A) Glioma cells were stably transduced with either shScramble or shMMP14 shRNAs and were examined for the expression of MMP14. Actin serves as loading control; (B) and (C) Flow cytometry analyses of cell distribution in the presence of attenuated form of MMP14. Student t-test with Bonferroni correction (*P < 0.05, **P < 0.01, ***P < 0.001).
U251 cells. Interestingly, Marimastat specifically inhibited the growth of glioma cells and had no effect on normal human astrocytes (NHA). Recently, it has been suggested that MMPs are involved in cell divisions [27]. To understand whether inhibition of glioma proliferation with Marimastat will affect the cell cycle, we stained Marimastat-treated glioma cells with PI dye. We found that Marimastat alters cell division of U87, U251, GBM39, and GBM43 glioma cells by increasing the number of tumor cells in G2 phase (Fig. 2D). Although the effect was most prominent in the presence of 100 nmol Marimastat, treatment of glioma cells with 1 and 10 nmol of Marimastat demonstrated G2 arrest as well.

**Effects of MMP14 genetic inhibition on cell division**

To investigate whether MMP14 regulates cell division, we knocked down U87 and U251 glioma cells using shRNA technology. We observed that protein and mRNA levels

![Graphs and images showing experimental data](image-url)

**Figure 4.** Temozolomide and radiation regulate MMP14 expression via microRNA374B in vitro and in vivo. Real time PCR analyses of microRNA374B expression in clinical samples (A) and in relation to MMP14 expression (B); In vitro, temozolomide and radiation treatment downregulate microRNA374B (C); Transfection of U87 and U251 reduces MMP14 expression at mRNA (D) and protein (E) levels; Direct binding of microRNA374B to 3′UTR of human MMP14 decreases luciferase expression at U251 (F).
of MMP14 were significantly decreased in the presence of anti-MMP14 shRNAs (Fig. S2). Moreover, silencing of MMP14 inhibited expression of downstream targets such as MMP2. To establish a relationship between inhibition of MMP14 and cell cycle arrest, we rescued a panel of stable MMP14 knockdown U87 and U251-based cells along with scrambled transfected clones (Fig. 3A). Inhibition of MMP14 with shRNA silencing led to cell cycle arrest of glioma cells in G2 phase (Fig. 3B and C). The number of cells in G2 phase increased from 15.1 ± 0.7 to 40.6 ± 3.9 (P < 0.001) for U87, and from 27 ± 0.8 to 53.8 ± 5.2 (P < 0.01) for U251 glioma cells.

**TMZ and ionizing XRT regulate expression of MMP14 via miRNA374B**

To identify profile of glioma-based miRNAs which regulate expression of MMP14 and are altered by TMZ/XRT treatment, we applied the mirFinder SAbioscience platform to the total miRNAs isolated from U87 cells treated with TMZ/ XRT (100 μmol/L+2 Gy/daily) or DMSO for 48 h. Based on relative quantification method (mean fold change >2 or <2), bioinformatical analyses, we determined that miRNA374B (~3.38-fold), miRNA374A (~2.1-fold), and miRNA150 (~4.1-fold) were decreased in treated U87 cells versus control groups. To validate that we measured expression of selected miRNAs using untreated/treated primary glioma specimens. As is shown in Figure 4A and B, miRNA374B expression correlates with a treatment status of patients and inversely with expression of MMP14. In vitro, treatment of U87 and U251 cells decreased expression of miRNA374B (Fig. 4C). Moreover, transfection of U87 and U251 with miRNA374B mimic downregulated MMP14 (Fig. 4D and E). Furthermore, binding of miRNA374B mimic to the 3UTR-MMP14 significantly reduced expression of luciferase in U251 cells, suggesting a strong relationship between MMP14mRNA expression and miRNA374B (Fig. 4F).

### The suppression of MMP14 in combination with TMZ and XRT improves the anti-glioma effect in vitro and in vivo

As previously shown in Figure 1, MMP14 is expressed more in TMZ/XRT treated rather than untreated GBMs. To assess the impact of MMP14 knockdown as an anti-cancer approach, we exposed U87 and U251 MMP14 knockdown cells to TMZ and XRT, and evaluated the effect of TMZ and XRT on cell viability by MTT assay. Compared to the cells transduced with scrambled shRNA, we observed that silencing of MMP14 inhibited the proliferation of tumor cells when treated with TMZ or XRT alone, as well as in combination (Fig. 5). These data demonstrate that MMP14 downregulation causes cell cycle arrest, and thus enhances the antiproliferative effect of chemotherapeutic agents such as TMZ and XRT.

It has been recently reported that MMP14 is upregulated in response to TMZ and XRT exposure [21] and silencing of MMP, including MMP14, decreases glioma tumor formation in vivo [28, 29]. To evaluate the tumorigenic activity of MMP14 ablated U87 and U251 cells, we implanted either scrambled or MMP14 attenuated cells intracranially (Figs. 6A and S3). We observed that in both U87 and U251 cell lines, silencing of MMP14 prolonged survival of mice with brain tumor xenografts (U87, P < 0.01; U251, P < 0.05). Moreover, silencing of MMP14 decreased formation and invasion of U251 cells in the brain (Fig. 6B). To assess whether TMZ and XRT will benefit from MMP14 silencing, we divided U251 glioma-bearing mice into four different treatment groups: shScramble, shMMP14, shScramble+TMZ+XRT, and shMMP14+TMZ+XRT. These mice were then treated with the indicated drugs and their survival was monitored. As demonstrated in Figure 6C, treatment of mice carrying U251shScramble xenografts with TMZ+XRT improved survival compared to the DMSO-treated animals (P < 0.01). Additionally, we demonstrated that treatment of the mice with U251shMMP14 xenografts with TMZ+XRT improved survival compared to the DMSO-
treated animals implanted with U251shMMP14 cells ($P < 0.05$). Finally, silencing of MMP14 in U251 model significantly prolonged survival of mice treated with TMZ+XRT compared to the U251 shScramble ($P < 0.009$) which results in low glioma proliferation (Fig. 6D, E, and F).

**Discussion**

Glioblastoma multiforme has a poor prognosis due to low sensitivity of tumor cells to the current therapeutic options such as TMZ and XRT [30]. One way to improve application of therapeutic modalities would be to identify genes responsible for brain tumor relapse and progression, and designing potential therapeutic approaches to inhibit their activity. Although the mechanism of tumor recurrence is still under investigation, it has been noticed that MMPs play an important role in tumor proliferation and invasion in many cancers including gliomas [31–33]. Recently, screening for MMP in clinical samples identified that some of these including MMP-2 and 9 are upregulated in tumor tissue compared to normal tissue [34–36] and their expression predicts tumor recurrence in several types of cancers [37–39]. Moreover, some reports recently suggested that expression of MMP14 downstream target such as MMP2 correlates with cancer progression in colon and breast cancers [11, 40]. In brain tumors, MMP2 serves as a predictor of tumor recurrence [32]. However, the interpretation of data may be very challenging as they do not account for the impact of conventional therapy such as TMZ and XRT. To demonstrate that MMP14 staining exhibits strong correlation with glioma
To understand how the inhibition of MMP14 affects TMZ and XRT, we knocked down the expression of MMP14 in several glioma cell lines. As expected, the treatment of glioma cells induced G2/M arrest at 24–48 h. To determine the relationship between MMP14 and cell cycle, we knocked down the MMP14 gene and performed cell cycle analysis via flow cytometry. Consistent with Marimastat inhibition data, silencing of MMP14 also induced G2/M arrest in all three glioma cell lines used in the study. Since U87 and U251 cells were established from various glioma patients having different mutations and growth properties, they may represent different sub-classes of glioma. Hence, our results may reveal a general phenomenon for various glioma subtypes.

Gliomagenesis is a complex process that relies on the intricate interplay between uncontrolled cell proliferation and microenvironmental factors, such as provision of growth factors and matrix reorganization. In all these steps, MMPs play a crucial role and therefore their inhibition can delay tumor formation or its experimental counterpart: xenografts establishment in animal models. In our study, we show that MMP14 shRNA interference delays tumor formation in the U251 cells and completely inhibits glioma establishment in the U87 model. Moreover, treatment of U251ko xenografts with TMZ and XRT extended their survival further, proving that such therapies can be given in combination for increased benefit. The different sensitivity of MMP-14 interference in tumor formation is to be expected considering glioma cells express a wide range of MMPs and MMP-14 contribution could vary between glioblastoma subtypes [41]. Henceforth, it is important to study the effect of MMP inhibition within different subtypes, once such models become available. That would help design individualized clinical trials to tease out the full effects of MMP inhibition since it has been shown that combination therapy of MMP-14 inhibitor with chemotherapy prolonged survival of GBM patients while Marimastat alone had no benefit in recurrent GBM [42].

In conclusion, we demonstrate that the attenuation of MMP14 inhibits glioma proliferation and improves therapeutic effect mediated by TMZ and XRT. Given the fact that some potential anticancer drugs which are in preclinical evaluation induce G2/M arrest, combining them with MMP14 inhibition could provide a rationale to improve efficacy of their application. Thus, the inhibition of MMP14 using chemical inhibition or via genetic silencing is an alternative approach for antiglioma therapy.

Acknowledgments

The authors thank Stacey Walker from technical service (Sigma Aldridge Corp) for helpful suggestions and discussions. We are also thankful to B. Yamini (University of Chicago, Neurosurgery) for valuable advice.

Conflict of Interest

None declared.

Reference

1. American Cancer Society. 2012. Cancer Facts & Figures. Available at http://www.cancer.org/downloads/STT/cancerfacts Figures2012.pdf (accessed 1 February 2013).
2. Kim, J. H., Y. Bae Kim, J. H. Han, K. G. Cho, S. H. Kim, S. S. Sheen, et al. 2012. Pathologic diagnosis of recurrent glioblastoma: morphologic, immunohistochemical, and molecular analysis of 20 paired cases. Am. J. Surg. Pathol. 36:620–628.
3. Alexiou, G. A., S. Tsiouris, S. Voulgaris, and A. P. Kyritsis. 2012. Fotopoulos A. The Role of Nuclear Medicine. Curr Radiopharm, Glioblastoma Multiforme Imaging.
4. Li, R., G. Li, L. Deng, Q. Liu, J. Dai, J. Shen, et al. 2010. IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncol. Rep. 23:1553–1559.
5. Hagemann, C., J. Anacker, R. I. Ernestus, and G. H. Vince. 2012. A complete compilation of matrix metalloproteinase expression in human malignant gliomas. World J. Clin Oncol. 3:67–79.
6. Kwiatkowska, A., M. Kijewska, M. Lipko, U. Hiberner, and B. Kaminska. 2011. Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression. Biochim. Biophys. Acta 1813:655–667.
7. Smith-Pearson, P. S., E. K. Greuber, G. Yogalingam, and A. M. Pendergast. 2010. Abi kinases are required for invadopodia formation and chemokine-induced invasion. J. Biol. Chem. 285:40201–40211.
8. Lehti, K., E. Allen, H. Birkedal-Hansen, K. Holmbeck, Y. Miyake, T. H. Chun, et al. 2005. An MT1-MMP-PDGF receptor-beta axis regulates mural cell investment of the microvasculature. Genes Dev. 19:979–991.
9. Devy, L., L. Huang, L. Naa, N. Yanamandra, H. Pieters, N. Frans, et al. 2009. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 69:1517–1526.
10. Deng, Y. P., W. Li, Y. L. Li, H. Xu, S. S. Liang, L. H. Zhang, et al. 2009. MT1-MMP up-regulates VEGF expression in human breast carcinoma MCF-7 cells and induces tumor angiogenesis. Zhonghua Zhong Liu Za Zhi 31:727–731.

11. Jiang, W. G., G. Davies, T. A. Martin, C. Parr, G. Watkins, M. D. Mason, et al. 2006. Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int. J. Mol. Med. 17:583–590.

12. Sabeh, F., I. Ota, K. Holmbeck, H. Birkedal-Hansen, P. Soloway, M. Balbin, et al. 2004. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J. Cell Biol. 167:769–781.

13. Takino, T., H. Tsuge, T. Ozawa, and H. Sato. 2010. MT1-MMP promotes cell growth and ERK activation through c-Src and paxillin in three-dimensional collagen matrix. Biochem. Biophys. Res. Commun. 396:1042–1047.

14. Tolde, O., D. Rosel, C. T. Mierke, D. Pankova, P. Vesely, et al. 2010. Neoplastic progression of the human breast cancer cell line G3S1 is associated with elevation of cytoskeletal dynamics and upregulation of MT1-MMP. Int. J. Oncol. 36:833–839.

15. Xia, W., S. Spector, L. Hardy, S. Zhao, A. Saluk, L. Alemane, et al. 2000. Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematomatological malignancies by BBL22, a benzazepine. Proc. Natl. Acad. Sci. USA 97:7494–7499.

16. Zhi, F., X. Chen, S. Wang, X. Xia, Y. Shi, W. Guan, et al. 2010. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur. J. Cancer 46:1640–1649.

17. Galban, S., B. Lemasson, T. M. Williams, F. Li, K. A. Heist, T. D. Johnson, et al. 2012. DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma. PLoS One 7:e35837.

18. Grommes, C., G. E. Landreth, M. Sastre, M. Beck, D. L. Feinstein, A. H. Jacobs, et al. 2006. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol. Pharmacol. 70:1524–1533.

19. Martinou, M., E. Giannopoulou, G. Malatara, A. A. Argyriou, H. P. Kalofonos, and D. Kardamakis. 2011. Ionizing radiation affects epidermal growth factor receptor signalling and metalloproteinase secretion in glioma cells. Cancer Genomics Proteomics 8:33–38.

20. Park, C. M., M. J. Park, H. J. Kwak, H. C. Lee, M. S. Kim, S. H. Lee, et al. 2006. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res. 66:8511–8519.

21. Trog, D., K. Yeghiazaryan, M. Fountoulakis, A. Friedlein, H. Moenkemann, N. Haertel, et al. 2006. Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells. Eur. J. Pharmacol. 542:8–15.

22. Gabelloni, P., E. Da Pozzo, S. Bendinelli, B. Costa, E. Nuti, F. Casalini, et al. 2010. Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. Neuroscientia 168:514–522.

23. Groves, M. D., V. K. Puduvalli, C. A. Conrad, M. R. Gilbert, W. K. Yung, K. Jaeckle, et al. 2006. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J. Neurooncol. 80:83–90.

24. Groves, M. D., V. K. Puduvalli, K. R. Hess, K. A. Jaeckle, P. Peterson, W. K. Yung, et al. 2002. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 20:1383–1388.

25. Uzzaman, M., G. Keller, and I. M. Germano. 2007. Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells. J. Neurosurg. 106:646–651.

26. Kil, W. J., D. Cerna, W. E. Burgan, K. Beam, D. Carter, P. S. Steeg, et al. 2008. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin. Cancer Res. 14:931–938.

27. Meierjohann, S., A. Hufnagel, E. Wende, M. A. Kleinschmidt, K. Wolf, P. Friedl, et al. 2010. MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation. Mol. Cancer 9:201.

28. Ito, E., C. Fujita, A. Iriune, M. Takeda, A. Madachi, S. Mori, et al. 2010. The role of MT2-MMP in cancer progression. Biochem. Biophys. Res. Commun. 393:222–227.

29. Nagaraju, G. P., A. K. Nalla, R. Gupta, S. Mohanam, M. Gujrati, D. H. Dinh, et al. 2011. siRNA-mediated downregulation of MMP-9 and uPAR in combination with radiation induces G2/M cell-cycle arrest in Medulloblastoma. Mol. Cancer Res. 9:51–66.

30. Milano, M. T., P. Okunieff, R. S. Donatello, N. A. Mohile, J. Sul, K. A. Walter, et al. 2010. Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 78:1147–1155.

31. Varga, I., G. Hutoczki, M. Petras, B. Scholtz, E. Miko, A. Kenyeres, et al. 2010. Expression of invasion-related extracellular matrix molecules in human glioblastoma versus intracerebral lung adenocarcinoma metastasis. Cent. Eur. Neurosurg. 71:173–180.
32. Komatsu, K., Y. Nakanishi, N. Nemoto, T. Hori, T. Sawada, and M. Kobayashi. 2004. Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathol. 21:105–112.

33. Chintala, S. K., J. C. Tonn, and J. S. Rao. 1999. Matrix metalloproteinases and their biological function in human gliomas. Int. J. Dev. Neurosci. 17:495–502.

34. Jaalinoja, J., R. Herva, M. Korpela, M. Hoyhtya, and T. Turpeenniemi-Hujanen. 2000. Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J. Neurooncol. 46:81–90.

35. Nakagawa, T., T. Kubota, M. Kabuto, K. Sato, H. Kawano, T. Hayakawa, et al. 1994. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J. Neurosurg. 81:69–77.

36. Choe, G., J. K. Park, L. Jouben-Steele, T. J. Kremen, L. M. Liau, H. V. Vinters, et al. 2002. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin. Cancer Res. 8:2894–2901.

37. Leinonen, T., R. Pirinen, J. Bohm, R. Johansson, and V. M. Kosma. 2008. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol. Histopathol. 23:693–700.

38. Ogbureke, K. U., P. M. Weinberger, S. W. Looney, L. Li, and L. W. Fisher. 2012. Expressions of matrix metalloproteinase-9 (MMP-9), dentin sialophosphoprotein (DSPP), and osteopontin (OPN) at histologically negative surgical margins may predict recurrence of oral squamous cell carcinoma. Oncotarget 3:286–298.

39. Seo, Y. S., J. J. Park, J. H. Kim, J. Y. Kim, J. E. Yeon, J. S. Kim, et al. 2007. Usefulness of MMP-9/TIMP-1 in predicting tumor recurrence in patients undergoing curative surgical resection for gastric carcinoma. Dig. Dis. Sci. 52:753–759.

40. Malhotra, S., E. Newman, D. Eisenberg, J. Scholes, R. Wieczorek, P. Mignatti, et al. 2002. Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer: a possible mechanism of neoplastic progression. Dis. Colon Rectum 45:537–543.

41. Verhaak, R. G., K. A. Hoadley, E. Purdom, V. Wang, Y. Qi, M. D. Wilkerson, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110.

42. Levin, V. A., S. Phuphanich, W. K. Yung, P. A. Forsyth, R. D. Maestro, J. R. Perry, et al. 2006. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J. Neurooncol. 78:295–302.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Figure S1. Distribution of MMP14 protein expression in untreated and TMZ/XRT treated GBM samples. Ten primary GBM and 8 recurrent GBM cases have been stained with antibodies recognize MMP14 human antigen. P = 0.055, Fisher’s exact test.

Figure S2. MMP14 downregulation induces G2M arrest. (A) U251 and U87 cells were transfected with different siRNAs targeting MMP14. Quantitative RT-PCR was carried out to verify the suppression of MMP14. (B) U251 and U87 were transiently transfected with either non-targeting shRNA (shScramble) or MMP14 sh4 (MMP14sh4). Western blotting was carried out to verify the suppression of MMP14.

Figure S3. MMP14 shRNA increases survival of U87 glioma bearing mice. Log rank test P < 0.001.